Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Men who take the androgen-blocker Zytiga have higher overall quality of life scores than those on chemotherapy.
Men who took Zytiga had higher quality of life scores and less pain than those treated with chemotherapy.
First targeted therapy may prolong survival of men with advanced prostate cancer.
These men lived for a median of 30 months compared to 26 months for white men.
The American Society of Clinical Oncology has released new prostate cancer guidelines.
Studies show African-American men may respond better to treatment and survive longer.
Clinical trials showed that adding Zytiga or docetaxel to hormone therapy improved survival.
Approval was based on LATITUDE trial of patients with metastatic high-risk castration-sensitive prostate cancer.
Two trials show that adding Zytiga to standard treatment for advanced prostate cancer reduces death risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.